293 related articles for article (PubMed ID: 20623786)
41. [Impact of PET/CT on precise radiotherapy planning for non-small cell lung cancer].
Gong HY; Yu JM; Fu Z; Li BS; Li JB; Liu TH
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):54-7. PubMed ID: 16737623
[TBL] [Abstract][Full Text] [Related]
42. Natural growth and disease progression of non-small cell lung cancer evaluated with 18F-fluorodeoxyglucose PET/CT.
Wang J; Mahasittiwat P; Wong KK; Quint LE; Kong FM
Lung Cancer; 2012 Oct; 78(1):51-6. PubMed ID: 22841591
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
44. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
45. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
[TBL] [Abstract][Full Text] [Related]
46. Dosimetric implications of the addition of 18 fluorodeoxyglucose-positron emission tomography in CT-based radiotherapy planning for non-small-cell lung cancer.
Vinod SK; Kumar S; Holloway LC; Shafiq J
J Med Imaging Radiat Oncol; 2010 Apr; 54(2):152-60. PubMed ID: 20518880
[TBL] [Abstract][Full Text] [Related]
47. The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer.
Everitt S; Plumridge N; Herschtal A; Bressel M; Ball D; Callahan J; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; Mac Manus M
Radiother Oncol; 2013 Mar; 106(3):288-91. PubMed ID: 23490268
[TBL] [Abstract][Full Text] [Related]
48. Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
Christensen JD; Colby TV; Patz EF
Cancer; 2010 Sep; 116(17):4095-102. PubMed ID: 20533438
[TBL] [Abstract][Full Text] [Related]
49. Impact of (18)F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: A prospective multicenter study.
Pommier P; Touboul E; Chabaud S; Dussart S; Le Pechoux C; Giammarile F; Carrie C
AJR Am J Roentgenol; 2010 Aug; 195(2):350-5. PubMed ID: 20651189
[TBL] [Abstract][Full Text] [Related]
50. Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
Bissonnette JP; Sun A; Grills IS; Almahariq MF; Geiger G; Vogel W; Sonke JJ; Everitt S; Manus MM
Lung Cancer; 2021 May; 155():136-143. PubMed ID: 33819859
[TBL] [Abstract][Full Text] [Related]
51. Defining target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional 18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography.
Hanna GG; van Sörnsen de Koste JR; Dahele MR; Carson KJ; Haasbeek CJ; Migchielsen R; Hounsell AR; Senan S
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):e71-80. PubMed ID: 22445302
[TBL] [Abstract][Full Text] [Related]
52. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
[TBL] [Abstract][Full Text] [Related]
53. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
[TBL] [Abstract][Full Text] [Related]
54. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
56. [¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients.
Petit SF; van Elmpt WJ; Oberije CJ; Vegt E; Dingemans AM; Lambin P; Dekker AL; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):698-705. PubMed ID: 20884128
[TBL] [Abstract][Full Text] [Related]
57. Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers.
Sun JS; Park KJ; Sheen SS; Yoon JK; Yoon SN; Lee KB; Hwang SC
Lung Cancer; 2009 Nov; 66(2):205-10. PubMed ID: 19203812
[TBL] [Abstract][Full Text] [Related]
58. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients.
Kim YK; Lee KS; Kim BT; Choi JY; Kim H; Kwon OJ; Shim YM; Yi CA; Kim HY; Chung MJ
Cancer; 2007 Mar; 109(6):1068-77. PubMed ID: 17311309
[TBL] [Abstract][Full Text] [Related]
59. Critical review of PET-CT for radiotherapy planning in lung cancer.
Senan S; De Ruysscher D
Crit Rev Oncol Hematol; 2005 Dec; 56(3):345-51. PubMed ID: 15990331
[TBL] [Abstract][Full Text] [Related]
60. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
